Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or
NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower
the amount of blood lost during burn surgery.